Prognostic Impact of the Advanced Lung Cancer Inflammation Index (ALI) in Metastatic Non-Small Cell Lung Cancer Treated with First Line Chemotherapy

Advanced Lung Cancer Inflammation Index: A Novel Comprehensive Biomarker of Host Status for Patients with Metastatic Colorectal Cancer

Numerous biomarkers that reflect host status have been identified for patients with metastatic colorectal cancer (mCRC). However, there has been a paucity of biomarker studies that comprehensively indicate body composition, nutritional assessment, and systemic inflammation status. The advanced lung cancer inflammation index (ALI), initially introduced as a screening tool for patients with non-small-cell lung cancer in 2013, emerges as a holistic marker encompassing all body composition, nutritional status, and systemic inflammation status. The index is calculated by the simple formula: body mass index × albumin value / neutrophil-to-lymphocyte ratio. Given its accessibility in routine clinical practice, the ALI has exhibited promising clinical utility in prognosticating outcomes for patients with multiple types of cancer. In this review, we focus on the significance of host status and the clinical applicability of the ALI in the treatment and management of patients with malignancies, including mCRC. We also suggest its potential in guiding the formulation of treatment strategies against mCRC and outline future perspectives.

Prognostic value of pretreatment advanced lung cancer inflammation index in non-small cell lung cancer: a meta-analysis

Purpose To identify the prognostic value of pretreatment advanced lung cancer inflammation index (ALI) in non-small cell lung cancer (NSCLC) including surgical patients who were diagnosed with early stage. Methods The PubMed, EMBASE and Web of Science electronic databases were searched up to January 12, 2022 for relevant studies. The hazard ratios (HRs) with 95% confidence intervals (CIs) were combined to assess the association between pretreatment ALI and overall survival (OS) or progression-free survival (PFS) of NSCLC patients. All statistical analyses were conducted by STATA 12.0 software. Results A total of 14 studies involving 3607 participates were included. The pooled results indicated that lower pretreatment ALI was significantly related with poorer OS (HR =2.20, 95% CI: 1.46-3.33, P<0.001) and PFS (HR =1.78, 95% CI: 1.49-2.13, P<0.001). Besides, subgroup analysis also demonstrated that lower pretreatment ALI was associated with worse OS in surgical (P<0.001) and non-metastatic (P<0.001) patients and worse PFS of surgical (P<0.001) NSCLC patients. Conclusion Pretreatment ALI was a novel and reliable prognostic indicator in NSCLC and lower pretreatment ALI predicted worse survival including patients diagnosed with early stage. However, more prospective high-quality studies are still needed to verify above findings.